Krystal Biotech Inc. (KRYS) shares plummeted 5.77% in pre-market trading on Monday, despite the company reporting better-than-expected third-quarter earnings. The biotechnology firm, which focuses on developing and commercializing novel treatments for patients suffering from serious diseases and conditions, saw its stock price drop sharply as investors appeared to weigh the company's future growth prospects against its current performance.

The company reported Q3 product revenue of $97.8 million, surpassing analyst expectations of $93.2 million. Net income for the quarter tripled to $79.4 million, or $2.66 per diluted share, significantly outperforming the FactSet consensus estimate of $0.95 per share. Krystal Biotech also maintained a strong gross margin of 96% for the quarter.

Despite these positive financial results, investors seemed to focus on other factors. The company provided updates on various drug developments and launches, including the expansion of VYJUVEK's eligible patient population in the U.S. and its launch in Germany, France, and Japan. Additionally, Krystal Biotech announced that the FDA granted platform technology designation to its gene therapy platform, which could potentially streamline future drug development processes.

The stock's decline may reflect profit-taking following recent gains or concerns about the sustainability of the company's growth rate. Investors might also be cautious about the ongoing pricing negotiations in various markets and the potential impact on future revenue. As Krystal Biotech continues to expand its global presence and advance its pipeline, including expected cystic fibrosis interim data readout in Q4 2025, the market appears to be reassessing the company's valuation in light of these developments and challenges.